264 results match your criteria Osteoporosis Involutional


Incidence of osteonecrosis of the jaw in Japanese osteoporosis patients taking minodronic acid.

J Bone Miner Metab 2019 Feb 4. Epub 2019 Feb 4.

Department of Internal Medicine, Research Institute and Practice for Involutional Diseases, 1610-1 Meisei, Misato, Azumino, Nagano, 399-8101, Japan.

Osteonecrosis of the jaw (ONJ) associated with bisphosphonate therapy is a rare but severe side effect in osteoporosis patients. Recently, the number of osteoporosis patients with ONJ has dramatically increased in Japan. This has contributed to an increase in the number of patients avoiding extractions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00774-019-00990-5DOI Listing
February 2019
2 Reads

Multiple vitamin deficiencies additively increase the risk of incident fractures in Japanese postmenopausal women.

Osteoporos Int 2018 Nov 27. Epub 2018 Nov 27.

Department of Internal Medicine, Research Institute and Practice for Involutional Diseases, 1610-1 Meisei, Misato, Azumino, Nagano, 399-8101, Japan.

The associations of multiple vitamin deficiencies on incident fractures were uncertain, the relationships between serum vitamin markers and incident bone fractures were investigated in Japanese postmenopausal women. The number of deficiencies was additively associated with incident fracture after adjustment for possible confounding factors including the treatment of osteoporosis.

Introduction: To evaluate the associations of multiple vitamin deficiencies on incident fractures, the relationships between serum vitamin markers and incident bone fractures were investigated in Japanese postmenopausal women. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00198-018-4784-2DOI Listing
November 2018
1 Read

Tight control: a new therapeutic strategy in the management of osteoporotic patients.

Osteoporos Int 2018 Dec 30;29(12):2677-2683. Epub 2018 Aug 30.

Kenézy Gyula University Hospital, University of Debrecen, Bartók Béla 2-26, Debrecen, H-4031, Hungary.

BMD changes in patients under tight control (monitored at 3-month intervals with adjustment of therapy guided by bone turnover markers) and routine management (controlled once a year) were compared. After 1 year, the femoral neck BMD increased significantly in the tight control compared to the routine management group.

Introduction: We intended to ascertain whether tight control (i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00198-018-4674-7DOI Listing
December 2018
11 Reads

Study design of multi-center, open-label randomized controlled, head-to-head trial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04.

J Bone Miner Metab 2018 Jul 17. Epub 2018 Jul 17.

Department of Internal Medicine, Research Institute and Practice for Involutional Diseases, Nagano, Japan.

We planned to conduct multi-center, open-labeled, blinded-endpoints, head-to-head randomized trial of minodronate and raloxifene to compare incidences of vertebral and non-vertebral fractures. The study is the Japanese Osteoporosis Intervention Trial protocol number 4 (JOINT-4). Here, we present the pre-fixed study design. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00774-018-0942-zDOI Listing
July 2018
8 Reads

A randomized, double-blind, placebo-controlled study of once weekly elcatonin in primary postmenopausal osteoporosis.

Curr Med Res Opin 2019 Mar 7;35(3):447-454. Epub 2018 Aug 7.

l Japan Osteoporosis Foundation , Tokyo , Japan.

Objective: Very few reports have described changes in bone mineral density (BMD) with long-term, once weekly administration of elcatonin, and its effects in reducing incident fractures remain unverified. Therefore, the efficacy and safety of once weekly elcatonin were examined over a 3 year period.

Methods: This was a multicenter, double-blinded, randomized, placebo-controlled study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/03007995.2018.1498780DOI Listing
March 2019
16 Reads

Correction to: Stimulation of intestinal calcium absorption by orally administrated vitamin D3 compounds: a prospective open-label randomized trial in osteoporosis.

Osteoporos Int 2018 05;29(5):1225

Department of Internal Medicine, Research Institute and Practice for Involutional Diseases, 1610-1 Meisei, Misato, Azumino, Nagano, 399-8101, Japan.

There were two errors in this article. 1. In the section "Ethical considerations", the registration number of the study was incorrectly given as UMIN000024492. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00198-018-4449-1DOI Listing

Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker.

Osteoporos Int 2018 05 8;29(5):1155-1163. Epub 2018 Feb 8.

Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Annual intravenous administration of zoledronic acid is used in the treatment of osteoporosis. A mathematical model was developed to predict bone mineral density up to 2 years after two annual doses of zoledronic acid from the early values of a bone resorption marker in osteoporosis patients.

Introduction: The measurement of bone mineral density (BMD) has been used as a surrogate marker instead of the observation of incident fractures to detect the efficacy of treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00198-018-4376-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5948273PMC
May 2018
3 Reads

Parathyroid hormone-related protein exhibits antioxidant features in osteoblastic cells through its N-terminal and osteostatin domains.

Bone Joint Res 2018 Jan;7(1):58-68

Bone and Joint Research Unit, The Institution of Health Research (IIS)-Fundación Jiménez Díaz, UAM, Madrid, Spain.

Objectives: Oxidative stress plays a major role in the onset and progression of involutional osteoporosis. However, classical antioxidants fail to restore osteoblast function. Interestingly, the bone anabolism of parathyroid hormone (PTH) has been shown to be associated with its ability to counteract oxidative stress in osteoblasts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1302/2046-3758.71.BJR-2016-0242.R2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805825PMC
January 2018
10 Reads

Stimulation of intestinal calcium absorption by orally administrated vitamin D3 compounds: a prospective open-label randomized trial in osteoporosis.

Osteoporos Int 2018 03 23;29(3):723-732. Epub 2017 Dec 23.

Department of Internal Medicine, Research Institute and Practice for Involutional Diseases, 1610-1 Meisei, Misato, Azumino, Nagano, 399-8101, Japan.

Intestinal fractional calcium absorption (FCA) was assessed before and after vitamin D3 treatment. Serum 1,25(OH)D concentration was significantly increased by plain vitamin D3 and reduced by eldecalcitol. The 1α hydroxyl calcidiol and eldecalcitol treatments increased FCA, which may be induced through direct stimulation of vitamin D receptors in the intestine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00198-017-4351-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834567PMC
March 2018
1 Read

Bisphosphonates prevent age-related weight loss in Japanese postmenopausal women.

J Bone Miner Metab 2018 Nov 13;36(6):734-740. Epub 2017 Dec 13.

Department of Geriatric Medicine, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bumkyo-ku, Tokyo, Japan.

Decline of body weight with aging is a major risk factor for frailty, osteoporosis and fracture, suggesting that treatment for osteoporosis may affect body composition. Recently, we have shown that 5-year treatment with raloxifene prevented age-related weight loss, suggesting some other drugs for osteoporosis may also prevent a decrease in body weight with aging. The present study aimed to identify the relationship between bisphosphonate treatment and body composition markers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00774-017-0891-yDOI Listing
November 2018
6 Reads

Optimal vitamin D intake for preventing serum 25-hydroxyvitamin D insufficiency in young Japanese women.

J Bone Miner Metab 2018 Sep 9;36(5):620-625. Epub 2017 Nov 9.

Department of Internal Medicine, Research Institute and Practice for Involutional Diseases, 1610-1 Meisei, Misato, Azumino, Nagano, 399-8101, Japan.

Populations of East Asian countries have been known to have low calcium intakes and low serum 25(OH)D concentrations, suggesting that Ca and vitamin D (VitD)-deficiencies are commonly observed. These nutritional imbalances may lead to low peak bone mass (PBM). The low PBM seen in Ca/VitD-deficient individuals may lead to osteoporosis, as well as an increased risk of fracture. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00774-017-0879-7DOI Listing
September 2018
2 Reads

The effect of once-yearly zoledronic acid on hip structural and biomechanical properties derived using computed tomography (CT) in Japanese women with osteoporosis.

Bone 2018 Jan 12;106:179-186. Epub 2017 Oct 12.

Japan Osteoporosis Foundation, 2-14 Odenma-cho, Nihonbashi Chuo-ku, Tokyo, Japan.

The effects of zoledronic acid on hip structural and biomechanical properties were evaluated in Japanese patients with osteoporosis by computed tomography (CT). The subjects included in this study were a subset of female subjects (zoledronic acid group, 49 subjects; placebo group, 53 subjects) in the phase 3 trial (ZONE study) who were available for multi-detector row CT (MDCT) scanning. Eligible subjects were those diagnosed with primary osteoporosis based on the Diagnostic Criteria for Primary Osteoporosis (2000) by the Japanese Society for Bone and Mineral Research and who had between one and four fractured vertebrae located between the fourth thoracic vertebra and the fourth lumbar vertebra. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bone.2017.10.013DOI Listing
January 2018
33 Reads

Old age causes de novo intracortical bone remodeling and porosity in mice.

JCI Insight 2017 Sep 7;2(17). Epub 2017 Sep 7.

Center for Osteoporosis and Metabolic Bone Diseases, University of Arkansas for Medical Sciences, and the Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, USA.

Decreased cortical thickness and increased cortical porosity are the key anatomic changes responsible for osteoporotic fractures in elderly women and men. The cellular basis of these changes is unbalanced endosteal and intracortical osteonal remodeling by the osteoclasts and osteoblasts that comprise the basic multicellular units (BMUs). Like humans, mice lose cortical bone with age, but unlike humans, this loss occurs in the face of sex steroid sufficiency. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/jci.insight.93771DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5621920PMC
September 2017
16 Reads

Low serum osteocalcin concentration is associated with incident type 2 diabetes mellitus in Japanese women.

J Bone Miner Metab 2018 Jul 1;36(4):470-477. Epub 2017 Aug 1.

Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Increasing evidence suggests that osteocalcin is involved in the regulation of glucose homeostasis. However, the relationship between serum osteocalcin levels and risk of incident type 2 diabetes mellitus is not clear. The objective of this study is to investigate whether serum osteocalcin levels are associated with the risk of incident type 2 diabetes mellitus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00774-017-0857-0DOI Listing
July 2018
21 Reads

24-Month Open-Label Teriparatide Once-Weekly Efficacy Research Trial Examining Bone Mineral Density in Subjects with Primary Osteoporosis and High Fracture Risk.

Adv Ther 2017 07 19;34(7):1727-1740. Epub 2017 Jun 19.

Touto Sangenjaya Rehabilitation Hospital, Setagaya-ku, Tokyo, Japan.

Introduction: To clarify the additional efficacy and safety benefits of 24 months' treatment with the once-weekly formulation of teriparatide, which is currently used for 72 weeks.

Methods: This was a multicenter, open-label, single-arm study conducted in Japan. Subjects who were 65 years or older with prevalent vertebral fractures received once-weekly subcutaneous injection of 56. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12325-017-0568-x
Publisher Site
http://dx.doi.org/10.1007/s12325-017-0568-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504212PMC
July 2017
15 Reads

Analysis and detection of microporosities in aging bones in context to pharmaceutical treatment: A study in line of osteoporosis.

Pak J Pharm Sci 2016 Sep;29(5 Suppl):1763-1767

Department of Zoology, University of Karachi, Pakistan.

The objective of the current study was to evaluate the effects of nandrolone decanoate in terms of morphological changes in the diaphyseal region of appendicular skeleton long bone (femur) of aging female Albino rats with the help of innovatively designed histomorphometric tool of study being introduced first time mapped out micro porosities (lacunae) which tend to intensify as part of advanced aging denoting deterioration in osseous tissue. In fact our research trial has been in the line of involutional osteoporosis especially common in post-menopausal aged women, as to find out appropriate drug usefulness in the care and cure of this diseased state as per recommendation of FDA. An animal experimental research trial was done in strict accordance with the guidelines of the Institutional Animals Ethics Committee(IAEC) and all standard dietary protocols were observed . Read More

View Article

Download full-text PDF

Source
September 2016
11 Reads

Health state utility values and patient-reported outcomes before and after vertebral and non-vertebral fractures in an osteoporosis clinical trial.

Osteoporos Int 2017 06 6;28(6):1893-1901. Epub 2017 Mar 6.

Department of Internal Medicine, Research Institute and Practice for Involutional Diseases, Nagano, Japan.

We assessed the health state utility value (HSUV) reductions associated with vertebral fractures using data collected in the Japanese Osteoporosis Intervention Trial-03 (JOINT-03). Our analysis revealed that assessment of HSUVs after morphometric vertebral fracture is important to capture the burden of vertebral fractures.

Introduction: Evaluation of the HSUV after fracture is important to calculate the quality-adjusted life years (QALYs) of osteoporosis patients, which is essential information in the context of health economic evaluation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00198-017-3966-7DOI Listing
June 2017
5 Reads

Safety, pharmacokinetics, and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis.

J Bone Miner Metab 2017 Nov 20;35(6):675-684. Epub 2016 Dec 20.

Aoba hospital, 2-15-2, Taishido, Setagaya-ku, Tokyo, 154-0004, Japan.

Although once-yearly intravenous administration of zoledronic acid has been reported to inhibit bone resorption and increase bone mineral density, no studies have evaluated its effectiveness in treating osteoporosis in Japanese patients. Therefore, the purpose of this study was to investigate the pharmacokinetics and assess the safety of and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis. This was a single-administration study with a single-blind parallel-group design. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00774-016-0806-3DOI Listing
November 2017
13 Reads

Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study).

Osteoporos Int 2017 01 8;28(1):389-398. Epub 2016 Sep 8.

Research Institute and Practice for Involutional Diseases, 1610-1 Meisei, Misato, Azumino, Nagano, 399-8101, Japan.

In a 2-year randomized, placebo-controlled study of 665 Japanese patients with primary osteoporosis, once-yearly administration of zoledronic acid (5 mg) reduced the risk of new morphometric vertebral fractures.

Introduction: The purpose of this study was to determine the efficacy and safety of once-yearly intravenous infusion of ZOL in Japanese patients with primary osteoporosis.

Methods: This was a two-year multicenter, randomized, placebo-controlled, double-blind, parallel-group comparative study (ZONE Study). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00198-016-3736-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5206287PMC
January 2017
3 Reads

Comparison of concurrent treatment with vitamin K and risedronate compared with treatment with risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03.

J Bone Miner Metab 2017 Jul 2;35(4):385-395. Epub 2016 Aug 2.

Department of Internal Medicine, Research Institute and Practice for Involutional Diseases, Nagano, Japan.

The aim of this study was to investigate the efficacy of concurrent treatment with vitamin K and risedronate compared with treatment with risedronate alone in patients with osteoporosis and to explore subsets of patients for which concurrent treatment is particularly efficacious. Women with osteoporosis aged 65 years or older were recruited from 123 institutes in Japan and allocated to take either vitamin K (45 mg/day) and risedronate (2.5 mg/day or 17. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00774-016-0768-5DOI Listing
July 2017
31 Reads

Treatment responses with once-weekly teriparatide therapy for osteoporosis.

Osteoporos Int 2016 10 27;27(10):3057-62. Epub 2016 May 27.

National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan.

Unlabelled: Monitoring bone mineral density is useful to assess treatment response for osteoporosis, but it does not always reflect fracture prevention. Two types of bone mineral density thresholds were used to analyze data from a once-weekly teriparatide trial, and they appear to be useful indicators of treatment success for osteoporosis.

Introduction: This study aimed to clarify whether the criteria of treatment response could be used to evaluate treatment success with once-weekly teriparatide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00198-016-3640-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042992PMC
October 2016
4 Reads

Decreased rate of hip fracture and consequent reduction in estimated medical costs in Japan.

J Bone Miner Metab 2017 May 13;35(3):351-353. Epub 2016 May 13.

Japan Osteoporosis Foundation, 11-2 Nihonbashi Kobune-cho, Chuo-ku, Tokyo, 3-0024, Japan.

The frequency of hip fractures associated with aging of the population is declining in many countries. Even in Japan, where this frequency has been increasing continually, a shift to decreasing frequency has been noted in recent reports. The objective of this study was to investigate the effects of this decrease and to estimate the number of hip fracture patients and the resulting reduction in national medical care expenditures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00774-016-0760-0DOI Listing
May 2017
2 Reads

Lack of cooperation between physicians and dentists during osteoporosis treatment may increase fractures and osteonecrosis of the jaw.

Curr Med Res Opin 2016 07 19;32(7):1261-8. Epub 2016 Apr 19.

e Department of Orthopaedic Surgery and Rheumatology, Nara Hospital , Kinki University Faculty of Medicine , Nara , Japan.

Objective: Our previous questionnaire-based survey suggested that discontinuation of antiresorptive agents before tooth extraction may increase adverse events and disturb osteoporosis treatment without completely preventing osteonecrosis of the jaw (O.N.J. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1185/03007995.2016.1170005DOI Listing
July 2016
11 Reads

Preventive effects of raloxifene treatment on agerelated weight loss in postmenopausal women.

J Bone Miner Metab 2017 Jan 11;35(1):108-113. Epub 2016 Jan 11.

Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bumkyo-ku, Tokyo, 113-8655, Japan.

Decline of body weight and body mass index (BMI) with aging is a major risk factor for osteoporosis and fracture, suggesting that treatment for osteoporosis may affect body composition. However, the effects of treatment for osteoporosis on body composition are not well known. The present study aimed to identify the relationship between raloxifene treatment and body composition markers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00774-015-0733-8DOI Listing
January 2017
2 Reads

Renal Phosphate Reabsorption is Correlated with the Increase in Lumbar Bone Mineral Density in Patients Receiving Once-Weekly Teriparatide.

Calcif Tissue Int 2016 Feb 19;98(2):186-92. Epub 2015 Oct 19.

National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.

In order to assess the changes in serum calcium and phosphate and the changes in renal tubular phosphate reabsorption (TmP/GFR) and to evaluate the association between these indices and the increase in bone mineral density (BMD) with once-weekly intermittent administration of teriparatide (TPTD), the results from the teriparatide once-weekly efficacy research (TOWER) trial were re-analyzed. The TOWER trial studied postmenopausal women and older men with osteoporosis. Patients were randomly assigned to receive TPTD 56. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00223-015-0073-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723624PMC
February 2016
4 Reads

Impact of Osteonecrosis of the Jaw on Osteoporosis Treatment in Japan: Results of a Questionnaire-Based Survey by the Adequate Treatment of Osteoporosis (A-TOP) Research Group.

Calcif Tissue Int 2015 Dec 26;97(6):542-50. Epub 2015 Jul 26.

Japan Osteoporosis Foundation, 11-2, Nihonbashi, Kobunacho, Chuo-ku, Tokyo, 103-0024, Japan.

Dentists request a discontinuation of antiresorptive agents, such as bisphosphonate, before and after tooth extractions to prevent osteonecrosis of the jaw (ONJ). However, little is known about how this affects ONJ and osteoporosis treatment and how medical professionals and dentists cooperate to treat ONJ in patients with osteoporosis. This study aimed to clarify the impact of ONJ on osteoporosis treatment in Japan. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s00223-015-0045
Web Search
http://link.springer.com/10.1007/s00223-015-0045-y
Publisher Site
http://dx.doi.org/10.1007/s00223-015-0045-yDOI Listing
December 2015
5 Reads

Comparison of expert and nonexpert physicians in the assessment of vertebral fractures using the semiquantitative method in Japan.

J Bone Miner Metab 2015 Nov 10;33(6):642-50. Epub 2014 Oct 10.

Bone and Joint Surgery, Seirei Hamamatsu General Hospital, 2-12-12 Sumiyoshi, Naka-ku, Hamamatsu, Shizuoka, 430-8558, Japan.

Assessment of vertebral fracture is critically important for the diagnosis and treatment of osteoporosis. This study aimed to clarify the effectiveness of the semiquantitative (SQ) method in the assessment of vertebral fractures in Japanese clinical practice. Forty-four physicians (seven experts and 37 nonexperts) assessed the spinal radiographs of 40 patients participating in the Adequate Treatment of Osteoporosis (A-TOP) Japanese Osteoporosis Intervention Trial (JOINT)-02 at the baseline, 12 months, and 24 months using the SQ method. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00774-014-0625-3DOI Listing
November 2015
5 Reads

Glucocorticoid-induced osteoporosis: 2013 update.

Reumatismo 2014 Jul 28;66(2):144-52. Epub 2014 Jul 28.

Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa.

Glucocorticoids are the most common cause of secondary osteoporosis leading to the so-called glucocorticoid-induced osteoporosis (GIO). A treatment with 10 mg/d of prednisone or equivalent for more than 3 months leads to a 7-fold increase in hip fractures and a 17-fold increase in vertebral fractures. The difference between bone quantity and quality in GIO makes bone mineral density measurements inadequate to detect patients at risk of fracture. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4081/reumatismo.2014.787DOI Listing
July 2014
1 Read

The problem of pain in old age.

Ann Agric Environ Med 2013 ;Spec no. 1:35-8

Department of Clinical Endoscopy, Institute of Rural Health, Lublin, Poland.

The elderly are more susceptible to feeling pain than young people. Pain is described as a complex, subjective feeling causing significant limitation of physical, psychical and social functioning. In the literature, there are many classifications of pain. Read More

View Article

Download full-text PDF

Source
March 2015
4 Reads

Management of postmenopausal osteoporosis and the prevention of fractures.

Panminerva Med 2014 Jun 19;56(2):115-31. Epub 2014 Jun 19.

Department of Obstetrics and Gynecology, Pisa University Hospital, Pisa, Italy -

Postmenopausal osteoporosis affects millions of women, being estrogen deficiency the key factor in the pathogenesis of involutional osteoporosis. Fracture prevention is one of the public health priorities worldwide. Different treatments for osteoporosis are available. Read More

View Article

Download full-text PDF

Source
June 2014
8 Reads

The effects of once-weekly teriparatide on hip geometry assessed by hip structural analysis in postmenopausal osteoporotic women with high fracture risk.

Bone 2014 Jul 13;64:75-81. Epub 2014 Apr 13.

National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan. Electronic address:

Weekly administration of teriparatide has been shown to reduce the risk of vertebral and non-vertebral fractures in patients with osteoporosis at higher fracture risk in Japan. However, its efficacy for hip fracture has not been established. To gain insight into the effect of weekly teriparatide on the hip, hip structural analysis (HSA) based on dual-energy X-ray absorptiometry (DXA) was performed using the data of 209 postmenopausal osteoporotic women who had participated in the original randomized, multicenter, double-blind, placebo-controlled trial assessing the effects of once-weekly 56. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S87563282140013
Publisher Site
http://dx.doi.org/10.1016/j.bone.2014.04.004DOI Listing
July 2014
4 Reads

Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT).

J Clin Endocrinol Metab 2014 Jul 19;99(7):2599-607. Epub 2014 Mar 19.

National Center for Global Health and Medicine (T.Nakam.), Tokyo 162-8655, Japan; Department of Medicine and Bioregulatory Sciences (T.Matsu.), University of Tokushima Graduate School of Medical Sciences, Tokushima 770-8503, Japan; Internal Medicine 1 (T.Su.), Shimane University Faculty of Medicine, Izumo 693-8501, Japan; Kenkoin Clinic (T.H.), Tokyo 104-0061, Japan; Department of Geriatric (T.Mi.), Osaka City University Medical School, Osaka 545-8585, Japan; Hori Hospital (I.G.), Yokohama 246-0021, Japan; Department of Orthopedic Surgery (H.Y.), Osaka University Graduate School of Medicine, Suita 565-0871, Japan; The First Department of Internal Medicine (Y.T.), University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan; Department of Orthopaedic Surgery Faculty of Medicine (S.T.), The University of Tokyo, Tokyo 113-8655, Japan; Department of Nuclear Medicine (T.So.), Kawasaki Medical School (M.F.), Kurashiki 701-0192, Japan; Tamana Central Hospital (T.Nakan.), Tamana 865-0064, Japan; Division of Radiology (M.I.), Nagasaki University School of Medicine, Nagasaki 852-8501, Japan; Department of Biostatistics (S.M.), Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; Osaka University Graduate School of Dentistry (T.Y.), Suita 565-0871, Japan; Daiichi Sankyo Co Ltd (H.T., K.W., T.O.), Tokyo 140-8710, Japan; and Research Institute and Practice for Involutional Diseases (M.S.), Azumino 399-8101, Japan.

Context: Denosumab 60 mg sc injection every 6 months for 36 months was well tolerated and effective in reducing the incidence of vertebral, nonvertebral, and hip fracture in predominantly Caucasian postmenopausal women with osteoporosis.

Objective: The objective of this phase 3 fracture study was to examine the antifracture efficacy and safety of denosumab 60 mg in Japanese women and men with osteoporosis compared with placebo.

Design And Setting: A randomized, double-blind, placebo-controlled trial with an open-label active comparator as a referential arm was conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2013-4175DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191553PMC
July 2014
50 Reads

Serum 25-hydroxyvitamin D level as an independent determinant of quality of life in osteoporosis with a high risk for fracture.

Clin Ther 2014 Feb 22;36(2):225-35. Epub 2014 Jan 22.

Department of Internal Medicine, Research Institute and Practice for Involutional Diseases, Nagano, Japan. Electronic address:

Background: Deteriorated quality of life (QOL) is a major problem in osteoporotic women. However, little is known regarding the determinants of QOL in patients with osteoporosis.

Objective: Our aim was to explore the role of vitamin D status on QOL score in osteoporosis with high fracture risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinthera.2013.12.007DOI Listing
February 2014
5 Reads

New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide.

Bone Res 2014 23;2:14043. Epub 2014 Dec 23.

Metabolic Bone Diseases Program, Division of Endocrinology, Department of Medicine, College of Physicians and Surgeons, Columbia University , New York, USA.

Daily 20-μg and once-weekly 56.5-μg teriparatide (parathyroid hormone 1-34) treatment regimens increase bone mineral density (BMD) and prevent fractures, but changes in bone turnover markers differ between the two regimens. The aim of the present study was to explain changes in bone turnover markers using once-weekly teriparatide with a simulation model. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/boneres201443
Publisher Site
http://dx.doi.org/10.1038/boneres.2014.43DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472137PMC
August 2015
5 Reads

Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen.

Bone 2014 Feb 29;59:44-52. Epub 2013 Oct 29.

National Center for Global Health and Medicine, Tokyo, Japan.

Oral risedronate has been shown to be effective in the treatment of osteoporosis when administered once-daily or once-weekly in Japan. This randomized, double-blind, multicenter 12-month study was conducted to compare the efficacy and tolerability of oral risedronate 75mg once-monthly with 2.5mg once-daily in Japanese patients with involutional osteoporosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bone.2013.10.017DOI Listing
February 2014
2 Reads

Effects of denosumab on cortical and trabecular microarchitecture: evidences from clinical studies.

Aging Clin Exp Res 2013 Oct 18;25 Suppl 1:S19-22. Epub 2013 Sep 18.

Department of Medical and Surgical Specialties and Dentistry, Second University of Naples, Naples, Italy,

Excess of bone remodeling is still the major pathogenic factor in involutional osteoporosis. This phenomenon is linked to an imbalance between neoformation (by osteoblasts) and resorption (by osteoclasts). Recently, research in drug development is focused on new and more "physiological" approach to balance bone remodeling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40520-013-0086-xDOI Listing
October 2013
1 Read

Calcidiol [25(OH)D3]: from diagnostic marker to therapeutical agent.

Curr Med Res Opin 2013 Nov 13;29(11):1565-72. Epub 2013 Sep 13.

Department of Surgery and Translational Medicine, University of Florence , Italy.

Objective: Osteoporosis is a skeletal disorder characterized by diminished bone strength, which results in an increased risk of fracture. Currently, osteoporosis is a public health priority due to the large number of individuals affected and the detrimental effect on quality of life. Primary osteoporosis, the most common form, usually results from age-related reduction in bone mineral strength. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1185/03007995.2013.838549DOI Listing
November 2013
2 Reads

FOXOs attenuate bone formation by suppressing Wnt signaling.

J Clin Invest 2013 Aug 15;123(8):3409-19. Epub 2013 Jul 15.

Division of Endocrinology and Metabolism, Center for Osteoporosis and Metabolic Bone Diseases, University of Arkansas for Medical Sciences and the Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, USA.

Wnt/β-catenin/TCF signaling stimulates bone formation and suppresses adipogenesis. The hallmarks of skeletal involution with age, on the other hand, are decreased bone formation and increased bone marrow adiposity. These changes are associated with increased oxidative stress and decreased growth factor production, which activate members of the FOXO family of transcription factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI68049DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3726166PMC
August 2013
9 Reads

Effects of weight-bearing activities on bone mineral content and density in children and adolescents: a meta-analysis.

J Bone Miner Res 2014 Feb;29(2):467-78

Institute of Training Science and Sport Informatics, German Sport University Cologne, Cologne, Germany.

Osteoporosis and associated fractures are a major health concern in Western industrialized nations. Exercise during growth is suggested to oppose the involutional bone loss later in life by increasing peak bone mass. The primary aim of the present meta-analysis was to provide a robust estimate of the effect of weight-bearing activities (WBAs) on bone mineral content (BMC) and areal bone mineral density (aBMD), during childhood and adolescence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jbmr.2036DOI Listing
February 2014
12 Reads

The vertebrae of prematurely aging mice as a skeletal model of involutional osteoporosis.

Histol Histopathol 2013 11 15;28(11):1473-81. Epub 2013 May 15.

Laboratorio de Metabolismo Mineral y Óseo, Instituto de Investigación Sanitaria (IIS)-Fundación Jiménez Díaz; Red Temática de Investigación Cooperativa en Envejecimiento y Fragilidad (RETICEF), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Oxidative stress in bone increases with age, which leads to bone frailty and a high fracture risk. Animal models show that early changes in trabecular structure occur in age-related osteopenia. These models might be valuable to assess the contribution of oxidative stress in age-related bone loss. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14670/HH-28.1473DOI Listing
November 2013
3 Reads

The effect of menopause on bone tissue in former swimmers and in non-athletes.

Adv Clin Exp Med 2012 Sep-Oct;21(5):645-52

Physical Education Department, Faculty of Physical Education in Biala Podlaska, Poland.

Background: An increased loss of bone density during the first years after menopause induces osteoporosis.

Objectives: The aim of the research presented in this paper was to ascertain the difference in the rate of involutional changes in bone tissue in former athletes and in non-athletes of the same age.

Material And Methods: The research involved 18 former swimmers and 18 females of similar age who had never practiced sports. Read More

View Article

Download full-text PDF

Source
February 2013
2 Reads

Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women.

Osteoporos Int 2013 Jan 24;24(1):219-26. Epub 2012 Oct 24.

Department of Internal Medicine, Research Institute and Practice for Involutional Diseases, 1610-1 Meisei, Misato, Azumino, Nagano, 399-8101, Japan.

Unlabelled: This study investigated the effects of a single administration of teriparatide on bone turnover markers in postmenopausal women. Teriparatide caused a transient increase in bone resorption and inhibition of bone formation followed by a subsequent increase in bone formation and a decrease in resorption that lasted at least 1 week.

Introduction: This study aims to investigate the effects of a single subcutaneous administration of teriparatide on bone turnover markers to elucidate why once weekly intermittent administration of teriparatide is effective on osteoporosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00198-012-2159-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3536955PMC
January 2013
2 Reads

For whom the bell tolls: distress signals from long-lived osteocytes and the pathogenesis of metabolic bone diseases.

Bone 2013 Jun 23;54(2):272-8. Epub 2012 Sep 23.

Division of Endocrinology & Metabolism, Center for Osteoporosis & Metabolic Bone Diseases, University of Arkansas for Medical Sciences, Little Rock, AR 72205-7199, USA.

Osteocytes are long-lived and far more numerous than the short-lived osteoblasts and osteoclasts. Immured within the lacunar-canalicular system and mineralized matrix, osteocytes are ideally located throughout the bone to detect the need for, and accordingly choreograph, the bone regeneration process by independently controlling rate limiting steps of bone resorption and formation. Consistent with this role, emerging evidence indicates that signals arising from apoptotic and old/or dysfunctional osteocytes are seminal culprits in the pathogenesis of involutional, post-menopausal, steroid-, and immobilization-induced osteoporosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bone.2012.09.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574964PMC
June 2013
1 Read

Eldecalcitol normalizes bone turnover markers regardless of their pre-treatment levels.

Curr Med Res Opin 2012 Sep 23;28(9):1547-52. Epub 2012 Aug 23.

Research Institute and Practice for Involutional Diseases, Nagano, Japan.

Background: Three-year treatment with eldecalcitol has been shown to improve lumbar and total hip bone mineral density (BMD), decrease bone turnover markers, and lower the incidences of vertebral and wrist fractures in patients with osteoporosis more than with treatment with alfacalcidol under vitamin D repletion. The purpose of this study was to determine whether there was a risk of eldecalcitol causing severely suppressed bone turnover in osteoporosis patients with low pre-treatment levels of bone turnover markers.

Methods And Results: Post-hoc analysis was conducted on the data from a 3-year, randomized, double-blind, active-comparator, clinical trial of eldecalcitol versus alfacalcidol under vitamin D repletion conducted in Japan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1185/03007995.2012.712506DOI Listing
September 2012
7 Reads

A multicenter randomized double-masked comparative study of different preparations of alendronate in osteoporosis - monthly (four weeks) intravenous versus once weekly oral administrations.

Curr Med Res Opin 2012 Aug 20;28(8):1357-67. Epub 2012 Jul 20.

Research Institute and Practice for Involutional Diseases, Azumino City, Nagano, Japan.

Objective: The aim of this study was to evaluate the efficacy and safety of intravenous alendronate (ALN) 900 µg every 4 weeks compared to oral ALN 35 mg once weekly.

Methods: A 52-week, multicenter, randomized, double-masked, active-controlled, parallel-group, non-inferiority study was conducted in a total of 325 Japanese patients aged 48-87 years with osteoporosis. Patients were randomly assigned to an intravenous ALN (iv, n = 162) group or oral ALN (po, n = 163) group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1185/03007995.2012.709838DOI Listing
August 2012
1 Read

The importance of absolute bone mineral density in the assessment of antiresorptive agents used for the prevention of osteoporotic fractures.

J Clin Densitom 2012 Oct-Dec;15(4):392-398. Epub 2012 Apr 20.

Division of Clinical Trial Design and Management, Translational Research Center, Kyoto University, Kyoto, Japan.

The usefulness of bone mineral density (BMD) monitoring during antiresorptive treatment is still controversial. This study aimed to determine which factors of change (absolute value or the percent change from the baseline) in BMD are associated with the risk of future fractures. A total of 565 postmenopausal osteoporosis who were treated antiresorptive drugs were included in this prospective observational study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jocd.2012.02.005DOI Listing
January 2013

Efficacy of antiresorptive agents for preventing fractures in Japanese patients with an increased fracture risk: review of the literature.

Drugs Aging 2012 03;29(3):191-203

Institute for Integrated Sports Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

The aim of the present review was to clarify the efficacy of currently available potent antiresorptive agents for preventing fractures in Japanese patients with an increased fracture risk. PubMed was used to search the literature for randomized controlled trials (RCTs), with the following search terms: fracture, etidronate, alendronate, risedronate, minodronate, raloxifene, bazedoxifene and Japan. The inclusion criteria were papers written in English, ≥50 subjects per group and a study period of ≥1 year. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/11597480-000000000-00000DOI Listing
March 2012
6 Reads

Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis.

Osteoporos Int 2012 Jun 20;23(6):1737-45. Epub 2011 Sep 20.

Third Department of Medicine, Teikyo University Chiba Medical Center, 3426-3 Anesaki, Ichihara, Chiba, 299-0111, Japan.

Unlabelled: Monthly minodronate at 30 or 50 mg had similar efficacy as 1 mg daily in terms of change in bone mineral density (BMD) and bone turnover markers with similar safety profiles. This new regimen provides patients with a new option for taking minodronate.

Introduction: Minodronate at a daily oral dose of 1 mg has been proven to have antivertebral fracture efficacy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00198-011-1782-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353114PMC
June 2012
3 Reads

[Secondary osteoporosis].

Authors:
Daisuke Inoue

Nihon Rinsho 2011 Jul;69(7):1295-9

Third Department of Medicine, Teikyo University Chiba Medical Center.

Involutional osteoporosis is one of the most prevalent diseases all over the world. Some osteoporotic patients, however, suffer from a co-existent disease that causes or accelerates development of osteoporosis. In contrast to primary osteoporosis, such "secondary" osteoporosis is more common in men. Read More

View Article

Download full-text PDF

Source
July 2011
2 Reads

[Doctor initiated clinical trial for obtaining evidences in treatment of osteoporosis: JOINT (Japanese Osteoporosis Intervention Trial) protocol].

Authors:
Masataka Shiraki

Nihon Rinsho 2011 Jul;69(7):1281-6

Research Institute and Practice for Involutional Diseases.

Due to the recent advances in the treatment of osteoporosis, clinicians can utilize many kinds of drugs to prevent fractures. Evidence of drug supplied to clinicians was mainly obtained from the results of the developmental studies. However, the evidence is still lack for the treatment in an individual patient in the"real world". Read More

View Article

Download full-text PDF

Source
July 2011
1 Read